Gelteq Limited GELS PHARMA
Company Overview
Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.36.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +48.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.93% |
| 1 Year: | 48.90% |
Stock Price Performance
| 1 Year: | -52.38% |
| 6 Months: | -13.31% |
| 3 Months: | +40.88% |
| 1 Month: | +21.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 57.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GELS Gelteq Limited PHARMA | 0.68 | -1.31 | $7.28M | 0.00% | -31.25% | -42.93% | 3.93% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 147.54K | 79.84K | 0 | 165.65K |
| Cost of Revenue | 94.87K | 48.92K | 0 | - |
| Gross Profit | 52.66K | 30.92K | 0 | - |
| Operating Expenses | 3.25M | 3.41M | 2.61M | 5.12M |
| Operating Income | -3.19M | -3.38M | -2.61M | -4.95M |
| EBITDA | -1.98M | -1.88M | -1.75M | -3.53M |
| Interest Expense | 174.50K | 403.52K | 585.12K | 1.89M |
| Pretax Income | -3.37M | -3.51M | -3.55M | -6.65M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -3.37M | -3.51M | -3.55M | -6.65M |
| Diluted EPS | -0.36 | -0.37 | -0.38 | -0.72 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 23.41M | 22.49M | 20.76M | 21.48M |
| Current Assets | 720.07K | 990.97K | 303.23K | 1.51M |
| Cash & Equivalents | 162.49K | 399.22K | 24.52K | 344.65K |
| Inventory | 95.20K | 95.20K | 0 | - |
| Receivables | 7.98K | 82.23K | 8.25K | 45.93K |
| Total Liabilities | 2.55M | 3.84M | 5.65M | 5.67M |
| Current Liabilities | 1.08M | 1.36M | 3.87M | 5.63M |
| Long Term Debt | 1.46M | 2.47M | 1.76M | 13.55K |
| Total Debt | 1.51M | 2.49M | 3.84M | 4.22M |
| Total Equity | 20.86M | 18.66M | 15.11M | 15.80M |
| Shares Outstanding | 9.44M | 9.44M | 9.44M | 10.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - |
| Investing Cash Flow | 0 | -75.93K | -148.17K | -736.84K |
| Financing Cash Flow | 1.49M | 2.03M | 843.94K | 6.45M |
| Capital Expenditure | - | -75.93K | -148.17K | -642.23K |
| Free Cash Flow | -1.51M | -1.85M | -1.22M | -6.16M |
| Net Change in Cash | -20.20K | 184.18K | -374.70K | 195.06K |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 35.7% | 38.7% | - | - |
| Operating Margin % | -2,165.1% | -4,232.9% | - | -2,989.0% |
| Net Margin % | -2,283.4% | -4,391.4% | - | -4,011.9% |
| ROE % | -16.2% | -18.8% | -23.5% | -42.0% |
| ROCE % | -14.3% | -16.0% | -15.4% | -31.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Two Sigma Securities, LLC | 0.31% | 33.24K | $18.68K |
| 2 | Jane Street Group, LLC | 0.28% | 30.16K | $16.95K |
| 3 | Wedbush Securities Inc | 0.19% | 20.00K | $11.24K |
| 4 | Morgan Stanley | 0.14% | 15.00K | $8.43K |
| 5 | Citadel Advisors Llc | 0.11% | 11.46K | $6.44K |
| 6 | UBS Group AG | - | 125 | $70 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GELS
Wondering what's happening in today's pre-market session? - ChartMill
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOeFlpQ2VtUGpyMmpCbnduMUtJTnlWeVFJbE5JanZfdnV3SXZXRWtQbHlHYk1uMVRQdmlORks5QldnWjN6akVkVGlBX3lwSDM3X3R4d2lzX0I0OV94S2VkS055Qm92azhQNFk3OVU3QW9heGUyRVgzYWo3eFNzVW1UUjlhV2RkbTlDMzQ5cU…
Gelteq sets up Guangdong hub as China biotech deals near $60B - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcF9ONmRSSEdLUHhmOUdPdi1GTTBlNjI0SmJlaV9JZGdzRUlTbnBiMkN5NFZtVlVkLUE0aUsxWWtLUy1yc1VObmlfdDFEbFpBc0xaRks3cjhqYUVnek1aY3NBSnFGX0s5cVY2WWg5YllBOGVXYUtvNG0wSmlLdVEyRGxhR0p4b3pqV0N4M2…
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOeXJ5QlNweS1UNWRwdC1qRzhQMktUTW5KTXluQXVSTnc3NjRqTzhhZk04Ym4zN1FONXQ0eDczOGVDM2tMQkVTbVdJYTdXdFlwNEdsU1lqQjRROFktQmxDX0ZFeUVRX1dSdGhmNWNvR3Rlb0c3WDZteWh3TjN5T2U4UVdUd3BDWWFCOXlGcn…
GELS Stock Rockets On Massive Volume As Traders Pile In - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFA2Qkt2ODcwNHluNU81S0tPaTJCamQzSGdmTTNSU3dwdWNfMzJ5eVM5azhQZ1RmRnRIbHhzS2xILTRtb21tOEQ3U2xzV1lBS3ZhM1BtSVUweUdRS3NJdzFxTC04emg5UDZzNW02cmVBMWt1b2hrd3c?oc=5" target="_blank">GELS Sto…
GELS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFB1c1h3Q3dRT0ttTElZV3RTLVoweUttQnhwUEZ4cDRvQWtqT0h2STdaMXNiS3Z1RnJrUUNHTkNSTkJyZm1TVkE?oc=5" target="_blank">GELS</a> <font color="#6f6f6f">Finviz</font>…
On Thursday, there are stocks with unusual volume. Let's take a look. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQNnVXU1k3VU1ON3ViOUJ6QmVENzlaTHBpYlFDQWp6Y1M3VDRlSUVxRXROLWRWQkpsUlR4WlVreGUxX2Vhemt3VDFiNlBCZ3RoZGVYc2R0NTFxb3dLbWNHNXlfZEZUUjRldWFPd3IwZzZCQTRFMk5TS251bUpxOHZteV9kb2NWOTBZcFZTX1…
GELS — Frequently Asked Questions
What is the current share price of Gelteq Limited (GELS)?
As of 2026-09-19 21:16 PDT, Gelteq Limited (GELS) trades at $0.68 on NasdaqCM. Its 52-week range is $0.39 to $1.60.
What is the market capitalisation of GELS?
Gelteq Limited (GELS) has a market capitalisation of $7.28M on NasdaqCM.
What is the P/E ratio of GELS?
GELS trades at a trailing price-to-earnings (P/E) ratio of -1.31. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.61.
What is the return on equity (ROE) of GELS?
GELS has a return on equity (ROE) of -42.93%. Its return on capital employed (ROCE) is -31.25%.
Is GELS a good stock to buy?
This page provides a data-driven analysis of Gelteq Limited (GELS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.